H.F. No. 91 Summary

• Modifies reimbursement for injectable drugs used to treat substance use disorder by allowing payment to be made to the administering facility, practitioner, administering pharmacy or pharmacist, or directly to the dispensing pharmacy.

• Establishes that claims must be submitted by the entity that purchases the drug directly from a wholesale distributor or manufacturer, or by the dispensing pharmacy if the drug is dispensed pursuant to a prescription and delivered to the practitioner for administration.

• Prohibits pharmacies from dispensing practitioner-administered injectable drugs directly to enrollees and requires administering practitioners and pharmacies to ensure claims are not duplicated.

• Requires the commissioner to contract with a vendor to conduct a cost of dispensing survey for Minnesota pharmacies by January 1, 2021, and repeat every three years, with results reported to legislative committees.

• Increases ingredient cost reimbursement by 1.8 percent for prescription and nonprescription drugs subject to the wholesale drug distributor tax.